Navigation Links
Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
Date:4/11/2012

WICHITA, Kan., April 11, 2012 /PRNewswire-USNewswire/ -- Riordan Clinic scientists Dr. Nina Mikirova, Dr. Joseph Casciari, and Dr. Ronald Hunninghake have patented a new technology that may help doctors determine the severity of fatigue in their patients.  The research, recently published in the January/February issue of the journal, Alternative Therapies, is entitled "The Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome by Serum Fluorescence Emission." 

Chronic fatigue syndrome (CFS) is characterized by long-lasting disabling fatigue. It includes non-specific symptoms such as weakness, malaise, subjective fever, sore throat, lymph node pain, and decreased memory. There are no conclusive diagnostic tests for CFS.  Since the underlying mechanism for CFS is not known, finding reliable biomarkers for diagnosing are important. 

The purpose of this study was to examine the use of serum nicotinamide adenine dinucleotide (NAD(P)H) levels as a metabolic marker of fatigue state and alterations in metabolism and homeostasis in CFS patients. 

The Riordan Clinic scientists have developed a method of determining NAD(P)H levels based on fluorescence emission of serum at 450 nm. Serum NAD(P)H concentrations were  compared for subjects with CFS and healthy controls.  NAD(P)H concentrations in the serum of CFS subjects averaged 8.0 +/- 1.4 (SD) uM while those in healthy controls averaged 10.8 +/- 0.8 (SD) uM, a statistically significant difference (p < 0.001). 

The sensitivity (detection of positives) and specificity (non-detection of negatives) of the test in matching CFS patients to control subjects at NAD(P)H cut-off of 9.5 uM were 0.73 and 0.98.   

The researchers also compared NAD(P)H concentrations to other endocrine and metabolic parameters. A factor analysis, based on the correlation matrix between all variables, demonstrated that the best correlations were between the NAD(P)H, serum coenzyme Q10 and urine pyrroles.

As coenzyme Q10 is the component of a complex series of reactions that occur within mitochondria, the function of Q10 ultimately is linked to the generation of energy within the cells.  The correlation between the lower level of coenzyme Q10 and lower NAD(P)H signals for patients with CFS suggests lower bioenergetics for these subjects.

An inverse correlation was found between the level of serum emission and the level of pyrroles in urine. The pyrroles are often elevated in patients with mental illness. This molecule is well known for bio-toxicity and is associated with emotional stress.

As a result of the study, researchers proposed that fatigue level and metabolic slowdown in CFS patients can be evaluated and monitored by serum NAD(P)H concentration measurements.

The measurement of the fluorescence of reduced nicotinamide adenine dinucleotide in serum provides a non-invasive assay to estimate metabolism and fatigue levels in CFS patients.  Following patient NAD(P)H levels over time may aid in selecting therapeutic strategies and monitoring treatment outcome.

To read this and other articles written by Riordan Clinic researchers, go to http://www.riordanclinic.org/research/journal-articles.shtml.

The Riordan Clinic is a progressive nutrition-based medical clinic located in Wichita, Kansas. For 36 years, the Riordan Clinic has integrated lifestyle and nutrition to help patients find the underlying causes of their illness. Since the inception in 1975, the mission has been clear and unwavering to "…stimulate an epidemic of health."

If you would like more information about this topic, please call Tiffany Hurley at (316) 682-3100 or email at thurley@riordanclinic.org.

 

 

 

 


'/>"/>
SOURCE Riordan Clinic
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The ABC Clinical Guide to Herbs Now Available Online
2. First targeted and programmable nanomedicine to show clinical antitumor effects published
3. inVentiv Health Completes Acquisition of Kforce Clinical Research
4. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
5. New imaging technique moves from lab to clinic
6. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
7. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
8. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
9. Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference
10. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
11. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
(Date:4/27/2017)... ... April 27, 2017 , ... Oncolinx, a spin-out of the ... has truly taken their cancer research out of this world. On April 22, ... Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, managed by the ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg ... Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads ... eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Therapeutics Summit ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA on September ... conference to learn about the latest advances in the treatment of various types ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
Breaking Biology News(10 mins):